Expressed Full-Length von Willebrand Factor Containing Missense Mutations Linked to Type IIB von Willebrand Disease Shows Enhanced Binding to Platelets

von Willebrand disease (vWD) variant type IIB is an inherited bleeding disorder resulting from the spontaneous binding of defective von Willebrand factor (vWF) to platelets in vivo. To identify the molecular basis for type IIB vWD, we used reverse transcription and the polymerase chain reaction to e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 1992-04, Vol.79 (8), p.2048-2055
Hauptverfasser: Kroner, Philip A., Kluessendorf, Mary L., Scott, J. Paul, Montgomery, Robert R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2055
container_issue 8
container_start_page 2048
container_title Blood
container_volume 79
creator Kroner, Philip A.
Kluessendorf, Mary L.
Scott, J. Paul
Montgomery, Robert R.
description von Willebrand disease (vWD) variant type IIB is an inherited bleeding disorder resulting from the spontaneous binding of defective von Willebrand factor (vWF) to platelets in vivo. To identify the molecular basis for type IIB vWD, we used reverse transcription and the polymerase chain reaction to examine the nucleotide sequence of the platelet glycoprotein (GP) lb-binding domain encoded by the vWF messenger RNA in an affected family, and in an unrelated affected individual. We identified two different missense mutations linked with expression of type IIB vWD. These mutations, which lead to Pro574→Leu and Val563→ Met substitutions, respectively, were each introduced into the full-length vWF expression vector pvW198, and both wild-type (wt) and mutant vWF were transiently expressed in COS-7 cells. Binding assays showed that both mutant proteins showed significant non-ristocetin-dependent spontaneous binding to platelets, and that complete binding was induced by low concentrations of ristocetin that failed to induce platelet binding by wt vWF. The vWF/platelet interaction was inhibited by the anti-vWF monoclonal antibody (MoAb) AvW3, and the anti-GPIb MoAb AP1, which both block vWF binding to platelets. These results show that the identified missense mutations are the likely basis for the expression of type IIB vWD in these affected individuals.
doi_str_mv 10.1182/blood.V79.8.2048.2048
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72893359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120730387</els_id><sourcerecordid>72893359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3228-63878e572e743fe0680c6a95c91ce3a05079ece81c07f6a1d3f52b7452f3a043</originalsourceid><addsrcrecordid>eNqFkc9uEzEQxi1EVULhESr5xG2D_6zXuydE0xQipQKJqD1ajne2MTh2sL2FPgmvi9OtVIkLl5nDN79vNPMhdE7JnNKWvd-6EPr5jezm7ZyReiov0IwK1laEMPISzQghTVV3kr5Cr1P6TgitOROn6JRyyTmvZ-jP8vchQkrQ46vRuWoN_i7v8H3w-NY6B9uofZG0ySHiRfBZW2_9Hb62hfEJ8PWYdbbBJ7y2_kexyQFvHg6AV6uLf20ubQJdmG-78Cvhpd9pbwpxYX1_9CzkV6czOMjpDToZtEvw9qmfoc3VcrP4XK2_fFotPq4rw1m5s-GtbEFIBrLmA5CmJabRnTAdNcA1EUR2YKClhsih0bTng2BbWQs2FLXmZ-jdZHuI4ecIKau9TQac0x7CmJRkbce56MqgmAZNDClFGNQh2r2OD4oSdcxDPeahSh6qVccoHkvhzp8WjNs99M_UFEDRP0w6lCPvLUSVjIXjW2wEk1Uf7H82_AXj6Z7a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72893359</pqid></control><display><type>article</type><title>Expressed Full-Length von Willebrand Factor Containing Missense Mutations Linked to Type IIB von Willebrand Disease Shows Enhanced Binding to Platelets</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kroner, Philip A. ; Kluessendorf, Mary L. ; Scott, J. Paul ; Montgomery, Robert R.</creator><creatorcontrib>Kroner, Philip A. ; Kluessendorf, Mary L. ; Scott, J. Paul ; Montgomery, Robert R.</creatorcontrib><description>von Willebrand disease (vWD) variant type IIB is an inherited bleeding disorder resulting from the spontaneous binding of defective von Willebrand factor (vWF) to platelets in vivo. To identify the molecular basis for type IIB vWD, we used reverse transcription and the polymerase chain reaction to examine the nucleotide sequence of the platelet glycoprotein (GP) lb-binding domain encoded by the vWF messenger RNA in an affected family, and in an unrelated affected individual. We identified two different missense mutations linked with expression of type IIB vWD. These mutations, which lead to Pro574→Leu and Val563→ Met substitutions, respectively, were each introduced into the full-length vWF expression vector pvW198, and both wild-type (wt) and mutant vWF were transiently expressed in COS-7 cells. Binding assays showed that both mutant proteins showed significant non-ristocetin-dependent spontaneous binding to platelets, and that complete binding was induced by low concentrations of ristocetin that failed to induce platelet binding by wt vWF. The vWF/platelet interaction was inhibited by the anti-vWF monoclonal antibody (MoAb) AvW3, and the anti-GPIb MoAb AP1, which both block vWF binding to platelets. These results show that the identified missense mutations are the likely basis for the expression of type IIB vWD in these affected individuals.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.V79.8.2048.2048</identifier><identifier>PMID: 1373334</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Base Sequence ; Blood Platelets - drug effects ; Blood Platelets - metabolism ; Cloning, Molecular ; DNA - blood ; DNA - genetics ; DNA - isolation &amp; purification ; Endothelium, Vascular - physiology ; Female ; Humans ; Leukocytes - metabolism ; Male ; Molecular Sequence Data ; Mutation ; Oligonucleotides, Antisense ; Pedigree ; Platelet Membrane Glycoproteins ; Polymerase Chain Reaction - methods ; Protein Binding ; Receptors, Cell Surface - drug effects ; Receptors, Cell Surface - metabolism ; Recombinant Proteins - isolation &amp; purification ; Recombinant Proteins - metabolism ; Ristocetin - pharmacology ; RNA - blood ; RNA - genetics ; RNA - isolation &amp; purification ; Transfection ; von Willebrand Diseases - blood ; von Willebrand Diseases - genetics ; von Willebrand Factor - genetics ; von Willebrand Factor - isolation &amp; purification ; von Willebrand Factor - metabolism</subject><ispartof>Blood, 1992-04, Vol.79 (8), p.2048-2055</ispartof><rights>1992 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3228-63878e572e743fe0680c6a95c91ce3a05079ece81c07f6a1d3f52b7452f3a043</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27906,27907</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1373334$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kroner, Philip A.</creatorcontrib><creatorcontrib>Kluessendorf, Mary L.</creatorcontrib><creatorcontrib>Scott, J. Paul</creatorcontrib><creatorcontrib>Montgomery, Robert R.</creatorcontrib><title>Expressed Full-Length von Willebrand Factor Containing Missense Mutations Linked to Type IIB von Willebrand Disease Shows Enhanced Binding to Platelets</title><title>Blood</title><addtitle>Blood</addtitle><description>von Willebrand disease (vWD) variant type IIB is an inherited bleeding disorder resulting from the spontaneous binding of defective von Willebrand factor (vWF) to platelets in vivo. To identify the molecular basis for type IIB vWD, we used reverse transcription and the polymerase chain reaction to examine the nucleotide sequence of the platelet glycoprotein (GP) lb-binding domain encoded by the vWF messenger RNA in an affected family, and in an unrelated affected individual. We identified two different missense mutations linked with expression of type IIB vWD. These mutations, which lead to Pro574→Leu and Val563→ Met substitutions, respectively, were each introduced into the full-length vWF expression vector pvW198, and both wild-type (wt) and mutant vWF were transiently expressed in COS-7 cells. Binding assays showed that both mutant proteins showed significant non-ristocetin-dependent spontaneous binding to platelets, and that complete binding was induced by low concentrations of ristocetin that failed to induce platelet binding by wt vWF. The vWF/platelet interaction was inhibited by the anti-vWF monoclonal antibody (MoAb) AvW3, and the anti-GPIb MoAb AP1, which both block vWF binding to platelets. These results show that the identified missense mutations are the likely basis for the expression of type IIB vWD in these affected individuals.</description><subject>Animals</subject><subject>Base Sequence</subject><subject>Blood Platelets - drug effects</subject><subject>Blood Platelets - metabolism</subject><subject>Cloning, Molecular</subject><subject>DNA - blood</subject><subject>DNA - genetics</subject><subject>DNA - isolation &amp; purification</subject><subject>Endothelium, Vascular - physiology</subject><subject>Female</subject><subject>Humans</subject><subject>Leukocytes - metabolism</subject><subject>Male</subject><subject>Molecular Sequence Data</subject><subject>Mutation</subject><subject>Oligonucleotides, Antisense</subject><subject>Pedigree</subject><subject>Platelet Membrane Glycoproteins</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Protein Binding</subject><subject>Receptors, Cell Surface - drug effects</subject><subject>Receptors, Cell Surface - metabolism</subject><subject>Recombinant Proteins - isolation &amp; purification</subject><subject>Recombinant Proteins - metabolism</subject><subject>Ristocetin - pharmacology</subject><subject>RNA - blood</subject><subject>RNA - genetics</subject><subject>RNA - isolation &amp; purification</subject><subject>Transfection</subject><subject>von Willebrand Diseases - blood</subject><subject>von Willebrand Diseases - genetics</subject><subject>von Willebrand Factor - genetics</subject><subject>von Willebrand Factor - isolation &amp; purification</subject><subject>von Willebrand Factor - metabolism</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9uEzEQxi1EVULhESr5xG2D_6zXuydE0xQipQKJqD1ajne2MTh2sL2FPgmvi9OtVIkLl5nDN79vNPMhdE7JnNKWvd-6EPr5jezm7ZyReiov0IwK1laEMPISzQghTVV3kr5Cr1P6TgitOROn6JRyyTmvZ-jP8vchQkrQ46vRuWoN_i7v8H3w-NY6B9uofZG0ySHiRfBZW2_9Hb62hfEJ8PWYdbbBJ7y2_kexyQFvHg6AV6uLf20ubQJdmG-78Cvhpd9pbwpxYX1_9CzkV6czOMjpDToZtEvw9qmfoc3VcrP4XK2_fFotPq4rw1m5s-GtbEFIBrLmA5CmJabRnTAdNcA1EUR2YKClhsih0bTng2BbWQs2FLXmZ-jdZHuI4ecIKau9TQac0x7CmJRkbce56MqgmAZNDClFGNQh2r2OD4oSdcxDPeahSh6qVccoHkvhzp8WjNs99M_UFEDRP0w6lCPvLUSVjIXjW2wEk1Uf7H82_AXj6Z7a</recordid><startdate>19920415</startdate><enddate>19920415</enddate><creator>Kroner, Philip A.</creator><creator>Kluessendorf, Mary L.</creator><creator>Scott, J. Paul</creator><creator>Montgomery, Robert R.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920415</creationdate><title>Expressed Full-Length von Willebrand Factor Containing Missense Mutations Linked to Type IIB von Willebrand Disease Shows Enhanced Binding to Platelets</title><author>Kroner, Philip A. ; Kluessendorf, Mary L. ; Scott, J. Paul ; Montgomery, Robert R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3228-63878e572e743fe0680c6a95c91ce3a05079ece81c07f6a1d3f52b7452f3a043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Animals</topic><topic>Base Sequence</topic><topic>Blood Platelets - drug effects</topic><topic>Blood Platelets - metabolism</topic><topic>Cloning, Molecular</topic><topic>DNA - blood</topic><topic>DNA - genetics</topic><topic>DNA - isolation &amp; purification</topic><topic>Endothelium, Vascular - physiology</topic><topic>Female</topic><topic>Humans</topic><topic>Leukocytes - metabolism</topic><topic>Male</topic><topic>Molecular Sequence Data</topic><topic>Mutation</topic><topic>Oligonucleotides, Antisense</topic><topic>Pedigree</topic><topic>Platelet Membrane Glycoproteins</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Protein Binding</topic><topic>Receptors, Cell Surface - drug effects</topic><topic>Receptors, Cell Surface - metabolism</topic><topic>Recombinant Proteins - isolation &amp; purification</topic><topic>Recombinant Proteins - metabolism</topic><topic>Ristocetin - pharmacology</topic><topic>RNA - blood</topic><topic>RNA - genetics</topic><topic>RNA - isolation &amp; purification</topic><topic>Transfection</topic><topic>von Willebrand Diseases - blood</topic><topic>von Willebrand Diseases - genetics</topic><topic>von Willebrand Factor - genetics</topic><topic>von Willebrand Factor - isolation &amp; purification</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kroner, Philip A.</creatorcontrib><creatorcontrib>Kluessendorf, Mary L.</creatorcontrib><creatorcontrib>Scott, J. Paul</creatorcontrib><creatorcontrib>Montgomery, Robert R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kroner, Philip A.</au><au>Kluessendorf, Mary L.</au><au>Scott, J. Paul</au><au>Montgomery, Robert R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expressed Full-Length von Willebrand Factor Containing Missense Mutations Linked to Type IIB von Willebrand Disease Shows Enhanced Binding to Platelets</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1992-04-15</date><risdate>1992</risdate><volume>79</volume><issue>8</issue><spage>2048</spage><epage>2055</epage><pages>2048-2055</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>von Willebrand disease (vWD) variant type IIB is an inherited bleeding disorder resulting from the spontaneous binding of defective von Willebrand factor (vWF) to platelets in vivo. To identify the molecular basis for type IIB vWD, we used reverse transcription and the polymerase chain reaction to examine the nucleotide sequence of the platelet glycoprotein (GP) lb-binding domain encoded by the vWF messenger RNA in an affected family, and in an unrelated affected individual. We identified two different missense mutations linked with expression of type IIB vWD. These mutations, which lead to Pro574→Leu and Val563→ Met substitutions, respectively, were each introduced into the full-length vWF expression vector pvW198, and both wild-type (wt) and mutant vWF were transiently expressed in COS-7 cells. Binding assays showed that both mutant proteins showed significant non-ristocetin-dependent spontaneous binding to platelets, and that complete binding was induced by low concentrations of ristocetin that failed to induce platelet binding by wt vWF. The vWF/platelet interaction was inhibited by the anti-vWF monoclonal antibody (MoAb) AvW3, and the anti-GPIb MoAb AP1, which both block vWF binding to platelets. These results show that the identified missense mutations are the likely basis for the expression of type IIB vWD in these affected individuals.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1373334</pmid><doi>10.1182/blood.V79.8.2048.2048</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 1992-04, Vol.79 (8), p.2048-2055
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_72893359
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Animals
Base Sequence
Blood Platelets - drug effects
Blood Platelets - metabolism
Cloning, Molecular
DNA - blood
DNA - genetics
DNA - isolation & purification
Endothelium, Vascular - physiology
Female
Humans
Leukocytes - metabolism
Male
Molecular Sequence Data
Mutation
Oligonucleotides, Antisense
Pedigree
Platelet Membrane Glycoproteins
Polymerase Chain Reaction - methods
Protein Binding
Receptors, Cell Surface - drug effects
Receptors, Cell Surface - metabolism
Recombinant Proteins - isolation & purification
Recombinant Proteins - metabolism
Ristocetin - pharmacology
RNA - blood
RNA - genetics
RNA - isolation & purification
Transfection
von Willebrand Diseases - blood
von Willebrand Diseases - genetics
von Willebrand Factor - genetics
von Willebrand Factor - isolation & purification
von Willebrand Factor - metabolism
title Expressed Full-Length von Willebrand Factor Containing Missense Mutations Linked to Type IIB von Willebrand Disease Shows Enhanced Binding to Platelets
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A01%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expressed%20Full-Length%20von%20Willebrand%20Factor%20Containing%20Missense%20Mutations%20Linked%20to%20Type%20IIB%20von%20Willebrand%20Disease%20Shows%20Enhanced%20Binding%20to%20Platelets&rft.jtitle=Blood&rft.au=Kroner,%20Philip%20A.&rft.date=1992-04-15&rft.volume=79&rft.issue=8&rft.spage=2048&rft.epage=2055&rft.pages=2048-2055&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.V79.8.2048.2048&rft_dat=%3Cproquest_cross%3E72893359%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72893359&rft_id=info:pmid/1373334&rft_els_id=S0006497120730387&rfr_iscdi=true